The
article
“Standing Guard”
was
published
on
the
PDA Letter
website
Sept.
26.
This
response
addresses
what
we
consider
misleading
conclusions
within
the
article.
As
manufacturers
of
recombinant
Factor
C
(rFC)
endotoxin
detection
assays—known
as
the
bioMérieux
ENDONEXT™
family
of
products,
we
are
committed
to
providing
an
accurate
portrayal
of
the
emerging
limulus
amebocyte
lysate
(LAL)
replacement
reagent
rFC.